Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness

View ORCID ProfileThomas D. Brothers, Malcolm Leaman, View ORCID ProfileMatthew Bonn, View ORCID ProfileDan Lewer, Jacqueline Atkinson, John Fraser, Amy Gillis, Michael Gniewek, Leisha Hawker, Heather Hayman, Peter Jorna, David Martell, Tiffany O’Donnell, Helen Rivers-Bowerman, Leah Genge
doi: https://doi.org/10.1101/2022.01.14.22269074
Thomas D. Brothers
1Department of Medicine (General Internal Medicine & Clinician-Investigator Program), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
2UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology & Health Care, University College London, London, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas D. Brothers
  • For correspondence: thomas.brothers{at}dal.ca
Malcolm Leaman
3North End Community Health Centre, Halifax, Nova Scotia, Canada
MMASc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Bonn
4Canadian Association of People who Use Drugs, Dartmouth, Nova Scotia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew Bonn
Dan Lewer
2UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology & Health Care, University College London, London, UK
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dan Lewer
Jacqueline Atkinson
3North End Community Health Centre, Halifax, Nova Scotia, Canada
NP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Fraser
3North End Community Health Centre, Halifax, Nova Scotia, Canada
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
6Department of Anesthesia, Pain Management & Perioperative Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Gillis
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Gniewek
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
7Direction 180, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leisha Hawker
3North End Community Health Centre, Halifax, Nova Scotia, Canada
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Hayman
3North End Community Health Centre, Halifax, Nova Scotia, Canada
NP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Jorna
8Nova Pharmacy, Halifax, Nova Scotia, Canada
BScPh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Martell
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
7Direction 180, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany O’Donnell
3North End Community Health Centre, Halifax, Nova Scotia, Canada
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Rivers-Bowerman
3North End Community Health Centre, Halifax, Nova Scotia, Canada
RN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leah Genge
3North End Community Health Centre, Halifax, Nova Scotia, Canada
5Department of Family Medicine, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
7Direction 180, Halifax, Nova Scotia, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background During a COVID-19 outbreak in the congregate shelter system in Halifax, Nova Scotia, Canada, a multidisciplinary health care team provided an emergency “safe supply” of pharmaceutical-grade medications and beverage-grade alcohol to facilitate isolation in COVID-19 hotel shelters for residents who are dependent on these substances. We aimed to evaluate (a) substances and dosages provided, and (b) effectiveness and safety of the program.

Methods We retrospectively reviewed medical records of all COVID-19 isolation hotel shelter residents during May 2021. We extracted data on medication and alcohol dosages provided each day. The primary outcome was residents prematurely leaving isolation against public health orders. Adverse events included (a) overdose; (b) intoxication; and (c) diversion, selling, or sharing of medications or alcohol.

Results Over 25 days, 77 isolation hotel residents were assessed (mean age 42 ± 14 years; 24% women). Sixty-two (81%) residents were provided medications, alcohol, or cigarettes. Seventeen residents (22%) received opioid agonist treatment medications (methadone, buprenorphine, or slow-release oral morphine) and 27 (35%) received hydromorphone tablets. Thirty-one (40%) residents received stimulant tablets with methylphenidate (27; 35%), dextroamphetamine (8; 10%), or lisdexamfetamine (2; 3%). Six residents (8%) received benzodiazepines. Forty-two (55%) residents received alcohol, including 41 (53%) with strong beer, three (3%) with wine, and one (1%) with hard liquor. Over 14 days in isolation, mean daily dosages increased of hydromorphone (45 ± 32 to 57 ± 42mg), methylphenidate (51 ± 28 to 77 ± 37mg), dextroamphetamine (33 ± 16 to 46 ± 13mg), and alcohol (12.3 ± 7.6 to 13.0 ± 6.9 standard drinks). Six residents (8%) left isolation prematurely, but four of those residents returned. Over 1,059 person-days in isolation, there were zero overdoses. Documented concerns regarding intoxication occurred six times (0.005 events/person-day) and medication diversion or sharing three times (0.003 events/person-day).

Conclusions An emergency safe supply and managed alcohol program, paired with housing, was associated with low rates of adverse events and high rates of successful completion of the 14-day isolation period in COVID-19 isolation hotel shelters. This supports the effectiveness and safety of emergency safe supply prescribing and managed alcohol in this setting.

Competing Interest Statement

MB reports personal fees from AbbVie, a pharmaceutical research and development company, and grants and personal fees from Gilead Sciences, a research-based biopharmaceutical company, outside of the submitted work.

Funding Statement

This project had no dedicated funding. TDB is supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a Canadian Institutes of Health Research Fellowship (CIHR-FRN# 171259), and through the Research in Addiction Medicine Scholars (RAMS) Program (National Institute of Health/National Institute on Drug Abuse; R25DA033211). DL is funded by a National Institute of Health Research Doctoral Research Fellowship (DRF-2018-11-ST2-016). Funders had no role in the in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript should be declared. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Requirements for full ethics review and individual participant consent were waived by the Nova Scotia Health Research Ethics Board, who determined this project to be quality assessment (REB FILE #: 1027156).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* These authors listed in alphabetical order

Data Availability

All data produced in the present work are contained in the manuscript

  • Abbreviations

    ABV
    Alcohol by volume
    BCCSU
    British Columbia Centre on Substance Use
    MOSH
    Mobile Outreach Street Health
    NORS
    National Overdose Response Service
    OAT
    Opioid agonist treatment
    SROM
    Slow-release oral morphine
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted January 17, 2022.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness
    Thomas D. Brothers, Malcolm Leaman, Matthew Bonn, Dan Lewer, Jacqueline Atkinson, John Fraser, Amy Gillis, Michael Gniewek, Leisha Hawker, Heather Hayman, Peter Jorna, David Martell, Tiffany O’Donnell, Helen Rivers-Bowerman, Leah Genge
    medRxiv 2022.01.14.22269074; doi: https://doi.org/10.1101/2022.01.14.22269074
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness
    Thomas D. Brothers, Malcolm Leaman, Matthew Bonn, Dan Lewer, Jacqueline Atkinson, John Fraser, Amy Gillis, Michael Gniewek, Leisha Hawker, Heather Hayman, Peter Jorna, David Martell, Tiffany O’Donnell, Helen Rivers-Bowerman, Leah Genge
    medRxiv 2022.01.14.22269074; doi: https://doi.org/10.1101/2022.01.14.22269074

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Addiction Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (430)
    • Allergy and Immunology (756)
    • Anesthesia (221)
    • Cardiovascular Medicine (3294)
    • Dentistry and Oral Medicine (364)
    • Dermatology (279)
    • Emergency Medicine (479)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
    • Epidemiology (13375)
    • Forensic Medicine (19)
    • Gastroenterology (899)
    • Genetic and Genomic Medicine (5153)
    • Geriatric Medicine (482)
    • Health Economics (783)
    • Health Informatics (3268)
    • Health Policy (1140)
    • Health Systems and Quality Improvement (1190)
    • Hematology (431)
    • HIV/AIDS (1017)
    • Infectious Diseases (except HIV/AIDS) (14627)
    • Intensive Care and Critical Care Medicine (913)
    • Medical Education (477)
    • Medical Ethics (127)
    • Nephrology (523)
    • Neurology (4925)
    • Nursing (262)
    • Nutrition (730)
    • Obstetrics and Gynecology (883)
    • Occupational and Environmental Health (795)
    • Oncology (2524)
    • Ophthalmology (724)
    • Orthopedics (281)
    • Otolaryngology (347)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (543)
    • Pediatrics (1302)
    • Pharmacology and Therapeutics (550)
    • Primary Care Research (557)
    • Psychiatry and Clinical Psychology (4212)
    • Public and Global Health (7504)
    • Radiology and Imaging (1705)
    • Rehabilitation Medicine and Physical Therapy (1013)
    • Respiratory Medicine (980)
    • Rheumatology (480)
    • Sexual and Reproductive Health (497)
    • Sports Medicine (424)
    • Surgery (548)
    • Toxicology (72)
    • Transplantation (236)
    • Urology (205)